Xtoro
(Finafloxacin)Phase 2Small molecule
Xtoro is one of 25 small molecule programs targeting Pyelonephritis. It is currently in Phase 2.
1
Indications
7
Total Trials
0
Active Trials
24
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
4
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Pyelonephritis
#DrugCompanyPhaseTrials
1Keflex
Eli LillyApproved
Doribax
ShionogiApproved
Maxipime
PfizerApproved
Rocephin
CConrado Roberto Hoffmann Filho
Approved
Ceftin
PPhiladelphia Eye Associates
Approved
Avycaz
PPhiladelphia Eye Associates
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Merrem
BB. Braun Medical Inc.
Approved
Carnitor
LLeadiant Biosciences, Inc.
Approved
Antibiotic
PfizerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ciprofloxacin1 trial
Efficacy and Safety1 trial
Intravenous1 trial
2 more indications
Regulatory
FDA Approval Timeline[4]
Dec 17, 2014
XTORO
NDA NDA206307
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Finafloxacin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]FDA Orange Book — Patent and exclusivity data for Xtoro. U.S. Food & Drug Administration.
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- FFabricio Lopes da Fonseca